Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) publishes a disclosure document relating to the rights issue of shares of approximately DKK 100 million before deduction of issue costs (the "Rights Issue"). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025.
Disclosure document
In connection with the Rights Issue the Company has prepared a disclosure document in accordance with article 1.4 db Regulation (EU) 2017/1129 of the European Parliament and of Counsil of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation"). The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation.
Today, Curasight announces that the disclosure document has been registered with the Danish Financial Supervisory Authority (Finanstilsynet) and made available on the Company's website. Holders of Subscription Rights shall adhere to the account agreement with their own Danish custodian institution or other financial intermediary, through which they hold existing shares. Application to subscribe for remaining shares must be made using the subscription form available on the Company's website (www.curasight.com), or in accordance with account holder's own bank and its respective instruction. The subscription form must be submitted via the investor's own account-holding bank or financial intermediary, in accordance with their respective procedures and deadlines.
Timetable for the Rights Issue
| 30 April 2025 | First day of trading excl. pre-emption rights |
| 1 May 2025 | Record date in the Rights Issue |
| 30 April 2025 - 14 May 2025 | Trading in subscription rights |
| 2 May 2025 - 16 May 2025 | Subscription period |
| 21 May 2025 | Estimated publication of the outcome of the Rights Issue |
Updated terms
The previously announced subscription terms have been amended to comply with technical requirements. These adjustments will have no direct impact on the Rights Issue. Under the updated terms, each holder of existing shares registered with Euronext Securities as of the record date, 1 May 2025, will be allocated forty-three (43) subscription rights for each existing share held. Eighteen (18) subscription rights will entitle the holder to subscribe for one (1) new share on a pre-emptive basis.